Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
228 hedge funds and large institutions have $3.63B invested in Amicus Therapeutics in 2023 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 95 increasing their positions, 66 reducing their positions, and 20 closing their positions.
65% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 20
45% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $9.83M
44% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 66
6% more funds holding
Funds holding: 216 → 228 (+12)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
3.95% less ownership
Funds ownership: 107.98% → 104.03% (-4%)
6% less capital invested
Capital invested by funds: $3.86B → $3.63B (-$224M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
+$104M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$30.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.04M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$5.54M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$5.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$78.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$78.1M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$33.8M |
| 4 |
Morgan Stanley
New York
|
-$29.8M |
| 5 |
O
OrbiMed
New York
|
-$23.3M |
FOLD Hedge Fund Activity: Q3 2023 in Review
228 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q3 2023, worth a combined $3.63B — down 5.8% from $3.86B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new FOLD positions and 20 closed out — a net gain of 13 holders — while 95 added to existing stakes and 66 trimmed.
The largest buyer was William Blair Investment Management, adding an estimated $104M. The largest seller was Deutsche Bank, cutting an estimated $78.8M.
- 228 institutional investors held Amicus Therapeutics (FOLD) as of Q3 2023, up from 216 in Q2 2023.
- Funds reported $3.63B of Amicus Therapeutics stock for Q3 2023, down 5.8% quarter-over-quarter.
- 33 funds opened new Amicus Therapeutics positions in Q3 2023 and 20 closed out, a net change of +13 holders.
- The largest Amicus Therapeutics buyer in Q3 2023 was William Blair Investment Management, an estimated $104M added.
- The largest Amicus Therapeutics seller in Q3 2023 was Deutsche Bank, an estimated $78.8M sold.
Based on aggregated 13F filings for Q3 2023.